Physician profile
Laura Toso
NPI 1801062708
$2,995.51
in general payments reported to CMS, 2019-2025
28 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $908 · 2021: $691 · 2022: $307 · 2023: $295 · 2024: $247 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $738.08 | 2020-2021 | |
| Abbvie INC. | $394.09 | 2019-2023 | Orilissa |
| Astellas Pharma US INC | $271.24 | 2019-2025 | Veozah |
| Renovia INC | $208.48 | 2020 | |
| Mayne Pharma Commercial LLC | $150.06 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.87 | 2019-2024 | |
| Hologic Sales and Service, LLC | $131.99 | 2021-2022 | |
| Organon LLC | $128.51 | 2021-2025 | Nexplanon |
| Daiichi Sankyo INC. | $105.84 | 2019-2020 | |
| Aspira Women'S Health INC | $105.76 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $92.04 | 2023-2025 | Myfembree, Gemtesa |
| Duchesnay USA Incorporated | $68.41 | 2019 | |
| Sage Therapeutics, LLC | $58.37 | 2024-2025 | Zurzuvae |
| Axonics, INC. | $43.11 | 2023 | Axonics |
| Channel Medsystems, INC. | $40.64 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $39.56 | 2019 | |
| Innovation Technologies INC | $36.79 | 2021 | |
| Olympus America INC. | $36.57 | 2019 | |
| Pfizer INC. | $34.88 | 2022 | |
| Exeltis, USA INC. | $27.48 | 2022 | |
| Avion Pharmaceuticals | $27.26 | 2021-2022 | |
| Radius Health, INC. | $21.14 | 2024 | Tymlos |
| Shield Therapeutics INC | $19.66 | 2023 | Accrufer |
| Amgen INC. | $17.70 | 2025 | Evenity |
| Smith+Nephew, INC. | $15.24 | 2023 | Pico |
| Amag Pharmaceuticals, INC. | $14.29 | 2019 | |
| Evofem Biosciences, INC. | $14.14 | 2021 | |
| Meditrina | $8.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Toso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.